Loading
A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease is a phase 2, interventional study registered as NCT07069595 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 78 participants, started 2026-02-26 and due to reach its primary completion in 2031-11-01. Interventions recorded: Datopotamab deruxtecan; Circulating tumor DNA (ctDNA) testing. Conditions listed: Breast Cancer; Residual Disease; Triple Negative Breast Cancer (TNBC); Stage II/III. Triple-negative eligibility wording from the registry: "* Histological confirmation of TNBC defined by ER/PR \<10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Datopotamab deruxtecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Datopotamab deruxtecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.